This database contains 457 studies, archived under the term: "drug therapy"
Click here to filter this large number of results.
Treatment of behavioral and psychological symptoms of Alzheimer-type dementia with Yokukansan in clinical practice
Hayashi, Yoshihito,
Ishida, Yasushi,
Inoue, Teruhiko,
Udagawa, Mitsutaka,
Takeuchi, Kouzou,
Yoshimuta, Hirofumi,
Kiue, Kouichirou,
Ninomiya, Yoshimasa,
Kawano, Jiro,
Sameshima, Tetsuro,
Kawahara, Takashi,
Goto, Isamu,
Shudo, Kenji,
Kurayama, Shigeki,
Nakamura, Jungo,
Okahara, Kazunori,
Mitsuyama, Yoshio
The efficacy and safety of the kampo medicine Yokukansan (YKS, TJ-54) in the treatment of behavioral and psychological symptoms of dementia (BPSD) were investigated in patients with Alzheimer’s disease (AD) in an open-label study. This study included 26 patients who had been diagnosed as having AD and were not treated with donepezil hydrochloride. These patients […]
Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe
Feldman, H. H.,
Doody, R. S.,
Kivipelto, M.,
Sparks, D. L.,
Waters, D. D.,
Jones, R. W.,
Schwam, E.,
Schindler, R.,
Hey-Hadavi, J.,
DeMicco, D. A.,
Breazna, A.
Background: There is some evidence that statins may have a protective and symptomatic benefit in Alzheimer disease (AD). The LEADe study is a randomized controlled trial (RCT) evaluating the efficacy and safety of atorvastatin in patients with mild to moderate AD.; Methods: This was an international, multicenter, double-blind, randomized, parallel-group study. Subjects had mild to […]
Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer’s disease: A 24-week, randomized, double-blind study
Farlow, Martin R.,
Salloway, Stephen,
Tariot, Pierre N.,
Yardley, Jane,
Moline, Margaret L.,
Wang, Qin,
Brand-Schieber, Elimor,
Zou, Heng,
Hsu, Timothy,
Satlin, Andrew
Background: Currently approved Alzheimer’s disease (AD) treatments have been reported to provide symptomatic benefit, without proven impact on clinical progression. We hypothesized that the loss of initial therapeutic benefit over time may be mitigated by higher doses of a cholinesterase inhibitor.; Objective: The aim of this study was to determine the effectiveness and tolerability of […]
Serotonin transporter triallelic genotype and response to citalopram and risperidone in dementia with behavioral symptoms
Dombrovski, Alexandre Y.,
Mulsant, Benoit H.,
Ferrell, Robert E.,
Lotrich, Francis E.,
Rosen, Jules I.,
Wallace, Meredith,
Houck, Patricia R.,
Mazumdar, Sati,
Pollock, Bruce G.
The risk/benefit ratio of pharmacotherapy for behavioral symptoms of dementia is questionable: second-generation antipsychotics are poorly tolerated, and the efficacy of alternative treatments, for example, selective serotonin-reuptake inhibitors (SSRIs), is uncertain. Biomarkers of treatment response may improve this risk/benefit ratio. The length polymorphism of the serotonin transporter promoter gene (5-HTTLPR/SLC6A4) may moderate tolerability of SSRIs […]
Low-dose divalproex in agitated patients with Alzheimer’s disease
Adequate treatment of behavioral disturbances in Alzheimer’s disease is both important and difficult. This report describes a case series that examined the effectiveness and safety of low-dose divalproex in the treatment of agitated patients with Alzheimer’s disease who were admitted to an inpatient geriatric psychiatry unit over a 1-year period. All patients had agitation due […]